Computational Antibody Papers
Filter by tags
developability
Filter by published year
2025
TitleKey points
2025-04-10
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning
- developability
- Viscosity prediction of high-concentration antibodies.
- Antibodies at low volume high concentration are needed for subcutaneous injections, which poses issues when antibodies are high-viscosity.
- They measured 229 mabs in 20mm histidine H-CL formulation, ph 6.0 at 150 mg/mL
- 162 were low viscosity (<20 cP) and 67 high viscosity (>20 cP)
- They employed the dataset to perform binary classification of the high and low viscosity data points
- They used structural features obtained from DeepSP for featurazition as well as one-hot encoded sequence.
- They used a set of predictive models, including simple neural networks, random forests, logistic regression and others.
- Their method performs well on independent test sets achieving >80% accuracy.
- In comparison to other methods that can be used as proxy (DeepSCM, SHARMA, TAP), their method does the best.
2025-02-20
ImmunoMatch learns and predicts cognate pairing of heavy and light immunoglobulin chains
- developability
- ngs
- Method to predict heavy light chain pairing.
- Heavy light chain pairing has long been posited to be random, or at the very least VERY promiscuous. Authors check that via training their model on different portions of the variable region and showing that there is signal where full sequences are used.
- Authors curated a set of ca. 233k positive heavy/light chain pairs from OAS. Negative samples were made by random shuffling - so they could occur in nature, just were not observed in this ds.
- They use Antiberta2 as a basis for training the classification model.
- The model achieves 0.75 and 0.66 ROC AUC on two test sets - so there seems to be some signal there.
- When the model is split between lamdbas/kappas, it does better - though lambda have signal for kappas (remember that lambda is a rescue rearrangement for not-working kappa).
- Naive B-cell pairs have less predictability than mature ones.
2025-02-03
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows
- developability
- Nice developability dataset with associated computational modeling.
- A total of 334 antibodies were initially characterized, with a subset of 43 antibodies selected for in vivo pharmacokinetic (PK) assessment. These data points included high-throughput developability assays and various physicochemical measurements.
- A multivariate regression model, using Partial Least Squares (PLS) regression, was developed. This model combined multiple in vitro measures (nonspecific interactions, self-association, and FcRn binding) to predict in vivo clearance, significantly improving PK correlation over individual assays.
- Authors study 171 Roche clinical studies representing 28 drugs for their ADA incidence.
- Authors demonstrate that ADA is highly context-specific with non-trivial inter-drug variation and factors such as disease or mode of action impacting the incidence.
- They train a random forest model on T-cell epitope predictions and a model combined with non-epitope features. The extended model, including non-epitope features performs better than the one that is solely sequence-based.
2025-01-21
PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning
- developability
- Computational framework to calculate descriptors correlating with certain developability features for early antibody screening.
- The framework calculates a number of sequence and structural descriptors.
- The correlations were demonstrated to bring value on a HIC and viscosity datasets.
- Exact calculation of descriptors takes time, so authors showed that it is possible to train a ML model to get the descriptors right away from sequence.
2025-01-21
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics
- developability
- Authors revisit computational calculations from sequence and structure to filter out clinical stage therapeutics as an alternative/refinement to the popular TAP metrics.
- Authors explain how the FvCSP charge asymmetry calculated in TAP might not be the ideal formulation.
- They introduce FV_CHML which as opposed to FvCSP is a difference between the net charges.
- Of the several computational metrics employed they show that the FV_CHML metric captures most of the clinical stage therapeutics.
- They analyse the effect of the isotype, demonstrating that for accurate pI calculations, constant region should be modeled and not only the Fv
- They propose four descriptors that appear to show good degree of separation of natural vs clinical antibodies and some correlation with the experimental values: 1. Patch_cdr_hyd - hydrophobicity of CDRs, not the same as in TAP 2. ens_charge_Fv - in lieu of PPC and PNC from TAP 3. Cdr_len - these separate repertoire from clinical abs. 4. Fv_chml - in lieu of FvCSP from TAP